Cardiovascular Systems Completes Coast Study Enrollment in Japan
Business Wire - Mon Dec 01, 7:01AM CST
--Study to Assess the Safety and Efficacy of New Coronary Micro Crown
CSII: 29.75 (+0.08)
U.S. Market for Peripheral Vascular Devices and Accessories Executive Summary: By 2020, the U.S. market for peripheral vascular devices will be worth over $6 billion
M2 - Tue Nov 11, 6:43AM CST
Research and Markets (http://www.researchandmarkets.com/research/3rwwd3/u_s_market_for) has announced the addition of the "U.S. Market for Peripheral Vascular Devices and Accessories (Executive Summary)" report to their offering. The peripheral vascular device market includes stents, percutaneous transluminal angioplasty (PTA) balloon catheters, atherectomy devices, chronic total occlusion devices, stent grafts, surgical grafts, arteriovenous (AV) access thrombectomy devices, inferior vena cava filters, catheters, guidewires, introducer sheaths, vascular closure devices and transcatheter embolization devices. These devices can be used for treating either coronary arterial or peripheral arterial disease (PAD), but only those devices used for peripheral procedures are included in this report. Older individuals and those who are obese have a higher risk of developing PAD. As result of a general increase in peripheral procedures and the development of new lower-limb treatments, the market for products such as stents and stent grafts will grow rapidly in the U.S. over the forecast period. Peripheral artery disease (PAD) remains a significantly under treated condition in the U.S and PAD is the leading cause of leg amputation. These factors will continue to drive growth in the peripheral vascular device market. In particular, the peripheral stent market is projected to grow over the forecast period. However, intense competition has led to price erosion and market penetration has moderated this once high growth segment. The launch of new technologies, including drug-eluting stents, will generate marginal revenues and only one company has sought FDA approval. In contrast, significant investments and acquisitions have taken place in the efforts of bringing the first drug-eluting balloon to the market, with Medtronic and C. R. Bard in a tight race to gain approval. Scope - Competitor Analysis - Identified Strategic Opportunities - Market Overview by Segment - Trend Analysis by Segment - Market Drivers & Limiters - Mergers & Acquisitions - Customer Feedback and Market Monitoring Main Segments Included: - Peripheral Vascular Stent Market - PTA Balloon Catheter Market - Atherectomy Device Market - Chronic Total Occlusion (CTO) Device Market - Embolic Protection Device Market - Stent Graft Market - Surgical Graft Market - AV Access Thrombectomy Device Market - Inferior Vena Cava Filter Market - Diagnostic and Interventional Catheter Market - Diagnostic and Interventional Guidewire Market - Introducer Sheath Market - Vascular Closure Device Market - Transcatheter Embolization Device Market Companies Mentioned - ALN International Inc. - Abbott Laboratories - AccessClosure - AngioDynamics - AngioScore - Angiotech - Argon Medical - Arstasis - Artegraft - Asahi Intecc USA - Atrax - Atrium Medical - B. Braun - Boston Scientific - C. R. Bard - Cardiovascular Systems Inc - Cardiva CeloNova Biosciences - Cook Medical - Cordis - Covidien - Endologix - IDEV Technologies - LeMaitre Vascular - MEDRAD - Maquet - Marine Polymer Technologies - Medtronic - Morris Innovative - Penumbra - Pfizer For more information visit http://www.researchandmarkets.com/research/3r...market_for About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
BSX: 13.13 (+0.07), ABT: 45.70 (-0.02), MDT: 74.08 (+0.31), CSII: 29.75 (+0.08), LMAT: 7.57 (+0.12)
Update: Cardiovascular Systems Fiscal 2015 Q1 Earnings
Andy Batts - at Seeking Alpha - Wed Nov 05, 10:52AM CST
CSII: 29.75 (+0.08)
Cardiovascular Systems Up 14.9% Since SmarTrend Uptrend Call (CSII)
Comtex SmarTrend(R) - Mon Nov 03, 9:58AM CST
SmarTrend identified an Uptrend for Cardiovascular Systems (NASDAQ:CSII) on October 17th, 2014 at $27.13. In approximately 2 weeks, Cardiovascular Systems has returned 14.93% as of today's recent price of $31.18.
CSII: 29.75 (+0.08)
Cardiovascular Systems Receives CE Mark for Stealth 360(R) Peripheral Orbital Atherectomy System
Business Wire - Mon Nov 03, 9:45AM CST
Cardiovascular Systems, Inc. (CSI) (NASDAQ: CSII), today announced that it has received CE (Conformite Europeenne) Mark for its Stealth 360 Orbital Atherectomy System (OAS). Stealth 360 is a percutaneous OAS that is indicated to treat patients who suffer from peripheral arterial disease (PAD).
CSII: 29.75 (+0.08)
Cardiovascular Systems (CSII) Jumps: Stock Rises 6.3% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Nov 03, 8:46AM CST
Cardiovascular Systems (CSII) was a big mover last session, with shares rising over 6% on the day.
ICUI: 83.38 (+1.63), CSII: 29.75 (+0.08), ABAX: 58.48 (+0.22), GWPH: 68.08 (+1.82)
Cardiovascular Systems provides fiscal Q2 guidance after FQ1 results
Seeking Alpha - at Seeking Alpha - Thu Oct 30, 9:38AM CDT
CSII: 29.75 (+0.08)
Cardiovascular Systems' (CSII) CEO Dave Martin on Q1 2015 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Wed Oct 29, 10:45PM CDT
CSII: 29.75 (+0.08)
Cardiovascular Systems beats Street 1Q forecasts
Automated Insights - Wed Oct 29, 4:54PM CDT
ST. PAUL, Minn. (AP) _ Cardiovascular Systems Inc. (CSII) on Wednesday reported a loss of $8.2 million in its fiscal first quarter.
CSII: 29.75 (+0.08)
Cardiovascular Systems (CSII) Q1 2015 Results - Earnings Call Webcast
SA Transcripts - at Seeking Alpha - Wed Oct 29, 3:40PM CDT
CSII: 29.75 (+0.08)
Cardiovascular Systems beats by $0.07, beats on revenue
Seeking Alpha - at Seeking Alpha - Wed Oct 29, 3:28PM CDT
CSII: 29.75 (+0.08)
Cardiovascular Systems Reports Fiscal 2015 First-Quarter Financial Results
Business Wire - Wed Oct 29, 3:00PM CDT
--Revenues grew to $41.4 million, a 39 percent increase over first quarter 2014 Coronary product revenues reached $5.0 million
CSII: 29.75 (+0.08)
Notable earnings after Wednesday’s close
Seeking Alpha - at Seeking Alpha - Tue Oct 28, 4:35PM CDT
CSGP: 185.62 (-1.43), CNW: 48.89 (+0.23), ACMP: 56.75 (-0.56), BGC: 14.82 (-0.61), DAC: 5.50 (-0.03), AIZ: 69.17 (-0.06), AEM: 23.65 (+0.65), ESRT: 17.67 (+0.02), CAR: 64.23 (-0.25), CWT: 24.96 (+0.34), AHL: 44.41 (-0.03), CLUB: 5.90 (-0.07), CAVM: 62.46 (+0.43), CJES: 13.39 (-0.29), FB: 80.77 (+0.16), AKAM: 64.34 (-0.25), EXR: 59.25 (-0.19), DWA: 22.72 (+0.05), EXL: 13.37 (+0.03), ANIK: 38.26 (+0.73), CLD: 9.45 (-0.26), ALL: 70.69 (-0.06), DRIV: 24.49 (+0.09), EQIX: 233.16 (+1.18), ESV: 30.39 (-0.89), ASGN: 33.66 (+0.33), AUY: 3.89 (+0.15), ACHC: 62.92 (+0.34), CALX: 10.21 (-0.17), CSII: 29.75 (+0.08), AFOP: 14.55 (+0.13), ARAY: 7.54 (+0.19), AEGN: 18.29 (+0.06), ATML: 8.43 (+0.06), CENX: 25.00 (+0.35), CUZ: 11.55 (-0.03), CACI: 87.76 (+0.23), ACGL: 59.51 (-0.24), AXS: 51.56 (-0.34), BMR: 21.76 (-0.15), ARII: 51.33 (-0.30), CBG: 34.93 (-0.06), CW: 71.04 (+0.48), DRE: 20.46 (unch), ABX: 10.31 (+0.14), CBL: 19.72 (-0.19), CHDN: 95.07 (-0.13), CMO: 12.68 (-0.12), CATM: 39.58 (-0.03), BLKB: 44.81 (+0.24), BIDU: 230.98 (-2.18), EQY: 25.52 (+0.06), ARRS: 30.17 (+0.30), ALDW: 12.24 (-0.12), CRUS: 23.60 (unch), CEMP: 20.66 (+0.78), CRL: 63.59 (+0.33)
Cardiovascular Systems Enrolls First Seven Patients in Japan for Coast Study
Business Wire - Mon Oct 27, 1:45PM CDT
--Study to Assess Safety and Efficacy of New Coronary Micro Crown to Secure Regulatory Approval in Both Countries
CSII: 29.75 (+0.08)
Cardiovascular Systems reports on October 29
Seeking Alpha - at Seeking Alpha - Thu Oct 16, 12:09PM CDT
CSII: 29.75 (+0.08)
Cardiovascular Systems to Webcast Fiscal 2015 First-Quarter Earnings Conference Call Wednesday, October 29
Business Wire - Thu Oct 16, 11:11AM CDT
Cardiovascular Systems, Inc. (CSI) (NASDAQ:CSII) will host a live webcast of its fiscal 2015 first-quarter conference call on Wednesday, October 29, 2014, at 3:45 p.m. CT (4:45 p.m. ET). David Martin, President and Chief Executive Officer, and Larry Betterley, Chief Financial Officer, will discuss the company's results for its fiscal first quarter ended September 30, 2014, and its financial outlook. The company will issue a post-market earnings release prior to the call on October 29.
CSII: 29.75 (+0.08)
Cardiovascular Systems Shares Down 11.3% Since SmarTrend's Sell Call (CSII)
Comtex SmarTrend(R) - Wed Oct 01, 9:29AM CDT
SmarTrend identified a Downtrend for Cardiovascular Systems (NASDAQ:CSII) on September 15th, 2014 at $27.07. In approximately 2 weeks, Cardiovascular Systems has returned 11.29% as of today's recent price of $24.01.
CSII: 29.75 (+0.08)
MIC, MNKD, XLE, IGE, NG, CSII Are Seasonally Ripe To Go Down In the Next Five Weeks
M2 - Mon Sep 22, 3:56AM CDT
BUYINS.NET / www.squeezetrigger.com is monitoring the Seasonality of Genworth MI Canada Inc (NYSE:MIC), Mannkind Corp (NASDAQ:MNKD), Select Sector Spdr Fund (NYSE:XLE), Ishares S & P Gssi National (NYSE:IGE), NovaGold Resources Inc (NYSE:NG), Cardiovascular Systems Inc (NASDAQ:CSII) and each have a high seasonal probability to go Down in the next weeks. By identifying stocks that are poised to go up or down based on seasonal tendencies, traders can increase their odds of making money. SqueezeTrigger.com is able to analyze over 20 years of data in less than 1 second for any stock in the market and determine if the stock has a long or short seasonal bias, how many trading days the move is expected to last, the probability of that move and the percentage move the stock is expected to make based on the seasonal bias. The technology used to generate these predictions is available for a low monthly fee at:
NG: 2.82 (+0.10), MIC: 69.24 (+1.45), CSII: 29.75 (+0.08), IGE: 38.64 (-0.43), MNKD: 5.68 (+0.18), XLE: 80.13 (-0.59)
Cardiovascular Systems reports departure of board chair Dr Glen D. Nelson
M2 - Thu Sep 18, 7:20AM CDT
Medical device company Cardiovascular Systems